Zoetis Inc. NYSE:ZTS

Zoetis stock price today

$155.97
-8.62
-5.24%
Financial Health
0
1
2
3
4
5
6
7
8
9

Zoetis stock price monthly change

-8.06%
month

Zoetis stock price quarterly change

-8.06%
quarter

Zoetis stock price yearly change

-16.40%
year

Zoetis key metrics

Market Cap
73.53B
Enterprise value
79.30B
P/E
30.67
EV/Sales
8.66
EV/EBITDA
20.59
Price/Sales
8.11
Price/Book
14.24
PEG ratio
1.56
EPS
5.19
Revenue
8.73B
EBITDA
3.56B
Income
2.39B
Revenue Q/Q
9.5%
Revenue Y/Y
7.90%
Profit margin
26.55%
Oper. margin
36.45%
Gross margin
68.87%
EBIT margin
36.45%
EBITDA margin
40.84%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Zoetis stock price history

Zoetis stock forecast

Zoetis financial statements

Zoetis Inc. (NYSE:ZTS): Profit margin
Jun 2023 2.18B 671M 30.78%
Sep 2023 2.15B 596M 27.71%
Dec 2023 2.21B 525M 23.72%
Mar 2024 2.19B 599M 27.35%
Zoetis Inc. (NYSE:ZTS): Analyst Estimates
Sep 2025 2.45B 754.32M 30.67%
Oct 2025 2.43B 744.40M 30.52%
Dec 2025 2.48B 717.32M 28.82%
Mar 2026 2.42B 726.95M 30.04%
  • Analysts Price target

  • Financials & Ratios estimates

1.04%
Yield TTM
Zoetis Inc. (NYSE:ZTS): Payout ratio
Payout ratio 31.44%
Zoetis Inc. (NYSE:ZTS): Dividend Yield
2019 0.5%
2020 0.48%
2021 0.41%
2022 0.89%
2023 0.76%
Zoetis Inc. (NYSE:ZTS): Debt to assets
Jun 2023 13749000000 9.12B 66.39%
Sep 2023 14106000000 9.03B 64.03%
Dec 2023 14286000000 9.29B 65.06%
Mar 2024 14348000000 9.29B 64.79%
Zoetis Inc. (NYSE:ZTS): Cash Flow
Jun 2023 183M -80M -494M
Sep 2023 724M -271M -416M
Dec 2023 897M -210M -397M
Mar 2024 595M -131M -524M

Zoetis alternative data

Animal Health Medicines

Zoetis Inc. (NYSE:ZTS): Google Trends - Animal Health Medicines
19 Feb 2023 1755
26 Feb 2023 1835
5 Mar 2023 1763
12 Mar 2023 2766
19 Mar 2023 1835
26 Mar 2023 1745
2 Apr 2023 2914
9 Apr 2023 2887
16 Apr 2023 2935
23 Apr 2023 1895
30 Apr 2023 1793
7 May 2023 1904
14 May 2023 1763
21 May 2023 1724
28 May 2023 2776
4 Jun 2023 2755
11 Jun 2023 0686
18 Jun 2023 0757
25 Jun 2023 2775
2 Jul 2023 1747

Numbers represent search interest relative to the highest point on the chart for the given region and time.

A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.

Zoetis Inc. (NYSE:ZTS): Job openings
Aug 2023 210
Sep 2023 180
Oct 2023 191
Nov 2023 213
Dec 2023 187
Jan 2024 132
Feb 2024 189
Apr 2024 200
May 2024 191
Jun 2024 238
Jul 2024 209
Dec 2024 227
Jan 2025 185
Feb 2025 234
May 2025 364
Jul 2025 232
Aug 2025 191
Zoetis Inc. (NYSE:ZTS): Employee count
Aug 2023 13,800
Sep 2023 13,800
Oct 2023 13,800
Nov 2023 13,800
Dec 2023 13,800
Jan 2024 13,800
Feb 2024 13,800
Mar 2024 14,100
Apr 2024 14,100
May 2024 14,100
Jun 2024 14,100
Jul 2024 14,100

Zoetis other data

89.00% -0.88%
of ZTS is owned by hedge funds
424.26M -3.82M
shares is hold by hedge funds

Zoetis Inc. (NYSE:ZTS): Insider trades (number of shares)
Period Buy Sel
Dec 2023 0 3423
Jan 2024 0 923
Feb 2024 0 17134
Mar 2024 0 2293
Apr 2024 0 923
Nov 2024 0 3477
Transaction Date Insider Security Shares Price per share Total value Source
Option
POLZER ROBERT J officer: Executive Vice President
Common Stock 2,420 $162.07 $392,209
Option
POLZER ROBERT J officer: Executive Vice President
Stock Option 1,057 N/A N/A
Option
POLZER ROBERT J officer: Executive Vice President
Stock Option 2,420 $162.07 $392,209
Option
POLZER ROBERT J officer: Executive Vice President
Common Stock 1,057 $160.62 $169,775
Sale
POLZER ROBERT J officer: Executive Vice President
Common Stock 3,477 $177.46 $617,028
Option
BANQUE SORIA ESTER officer: Executive Vice President
Restricted Stock Unit 895 N/A N/A
Option
BANQUE SORIA ESTER officer: Executive Vice President
Common Stock 895 N/A N/A
Option
JOSEPH WETTENY officer: Chief Financial Officer
Common Stock 20,333 N/A N/A
Option
JOSEPH WETTENY officer: Chief Financial Officer
Common Stock 7,693 N/A N/A
Option
JOSEPH WETTENY officer: Chief Financial Officer
Restricted Stock Unit 7,693 N/A N/A
Thursday, 26 December 2024
seekingalpha.com
Friday, 20 December 2024
zacks.com
zacks.com
Thursday, 19 December 2024
fool.com
Monday, 16 December 2024
zacks.com
Friday, 13 December 2024
zacks.com
fool.com
Thursday, 12 December 2024
businesswire.com
Thursday, 5 December 2024
youtube.com
Wednesday, 4 December 2024
zacks.com
zacks.com
Monday, 2 December 2024
seekingalpha.com
Friday, 29 November 2024
seekingalpha.com
Wednesday, 27 November 2024
zacks.com
Wednesday, 20 November 2024
seekingalpha.com
Monday, 18 November 2024
zacks.com
seekingalpha.com
Tuesday, 12 November 2024
youtube.com
Monday, 11 November 2024
fool.com
businesswire.com
Sunday, 10 November 2024
seekingalpha.com
Thursday, 7 November 2024
businesswire.com
Monday, 4 November 2024
zacks.com
seekingalpha.com
proactiveinvestors.com
accesswire.com
zacks.com
reuters.com
zacks.com
businesswire.com
  • What's the price of Zoetis stock today?

    One share of Zoetis stock can currently be purchased for approximately $155.97.

  • When is Zoetis's next earnings date?

    Unfortunately, Zoetis's (ZTS) next earnings date is currently unknown.

  • Does Zoetis pay dividends?

    Yes, Zoetis pays dividends and its trailing 12-month yield is 1.05% with 31% payout ratio. The last Zoetis stock dividend of $0.33 was paid on 1 Mar 2022.

  • How much money does Zoetis make?

    Zoetis has a market capitalization of 73.53B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.74% to 8.54B US dollars.

  • What is Zoetis's stock symbol?

    Zoetis Inc. is traded on the NYSE under the ticker symbol "ZTS".

  • What is Zoetis's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Zoetis?

    Shares of Zoetis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Zoetis's key executives?

    Zoetis's management team includes the following people:

    • Ms. Kristin C. Peck Chief Executive Officer & Director(age: 54, pay: $2,790,000)
    • Ms. Wafaa Mamilli Executive Vice President and Chief Information & Digital Officer(age: 58, pay: $2,600,000)
    • Mr. Roman Trawicki Executive Vice President and Pres of Global Manufacturing & Supply(age: 61, pay: $2,190,000)
    • Mr. Glenn C. David Group Pres & Executive Vice President(age: 53, pay: $1,530,000)
  • How many employees does Zoetis have?

    As Jul 2024, Zoetis employs 14,100 workers.

  • When Zoetis went public?

    Zoetis Inc. is publicly traded company for more then 12 years since IPO on 1 Feb 2013.

  • What is Zoetis's official website?

    The official website for Zoetis is zoetis.com.

  • Where are Zoetis's headquarters?

    Zoetis is headquartered at 10 Sylvan Way, Parsippany, NJ.

  • How can i contact Zoetis?

    Zoetis's mailing address is 10 Sylvan Way, Parsippany, NJ and company can be reached via phone at +973 8227000.

Zoetis company profile:

Zoetis Inc.

zoetis.com
Exchange:

NYSE

Full time employees:

14,100

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

10 Sylvan Way
Parsippany, NJ 07054

CIK: 0001555280
ISIN: US98978V1035
CUSIP: 98978V103